|
1
|
Mosharov EV, Borgkvist A and Sulzer D:
Presynaptic effects of levodopa and their possible role in
dyskinesia. Mov Disord. 30:45–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hely MA, Morris JG, Reid WG and
Trafficante R: Sydney multicenter study of Parkinson's disease:
Non-L-DOPA-responsive problems dominate at 15 years. Mov Disord.
20:190–199. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Finlay C and Duty S: Therapeutic potential
of targeting glutamate receptors in Parkinson's disease. J Neural
Transm (Vienna). 121:861–880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schaeffer E, Pilotto A and Berg D:
Pharmacological strategies for the management of levodopa-induced
dyskinesia in patients with Parkinson's disease. CNS Drugs.
28:1155–1184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dorszewska J, Prendecki M, Lianeri M and
Kozubski W: Molecular effects of L-dopa therapy in parkinson's
disease. Curr Genomics. 15:11–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spencer JP, Jenner P and Halliwell B:
Superoxide-dependent depletion of reduced glutathione by L-DOPA and
dopamine. Relevance to Parkinson's disease. Neuroreport.
6:1480–1484. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andican G, Konukoglu D, Bozluolcay M,
Bayulkem K, Firtiina S and Burcak G: Plasma oxidative and
inflammatory markers in patients with idiopathic Parkinson's
disease. Acta Neurol Belg. 112:155–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferreira PM, Militão GC and Freitas RM:
Lipoic acid effects on lipid peroxidation level, superoxide
dismutase activity and monoamines concentration in rat hippocampus.
Neurosci Lett. 464:131–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith AR, Shenvi SV, Widlansky M, Suh JH
and Hagen TM: Lipoic acid as a potential therapy for chronic
diseases associated with oxidative stress. Curr Med Chem.
11:1135–1146. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Araújo DP, Lobato Rde F, Cavalcanti JR,
Sampaio LR, Araújo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC
and Vasconcelos SM: The contributions of antioxidant activity of
lipoic acid in reducing neurogenerative progression of Parkinson's
disease: A review. Int J Neurosci. 121:51–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li DW, Li GR, Lu Y, Liu ZQ, Chang M, Yao
M, Cheng W and Hu LS: α-lipoic acid protects dopaminergic neurons
against MPP+-induced apoptosis by attenuating reactive oxygen
species formation. Int J Mol Med. 32:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Araújo DP, Lobato Rde F, Cavalcanti JR,
Sampaio LR, Araújo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC
and Vasconcelos SM: The contributions of antioxidant activity of
lipoic acid in reducing neurogenerative progression of Parkinson's
disease: A review. Int J Neurosci. 121:51–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Araújo DP, De Sousa CN, Araújo PV,
Menezes CE, Rodrigues Sousa FT, Escudeiro SS, Lima NB, Patrocínio
MC, Aguiar LM, Viana GS and Vasconcelos SM: Behavioral and
neurochemical effects of alpha-lipoic Acid in the model of
Parkinson's disease induced by unilateral stereotaxic injection of
6-ohda in rat. Evid Based Complement Alternat Med. 2013:5713782013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie CL, Wang WW, Zhang SF, Yuan ML, Che
JY, Gan J, Song L, Yuan WE and Liu ZG: Levodopa/benserazide
microsphere (LBM) prevents L-dopa induced dyskinesia by
inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned
Parkinson's rats. Sci Rep. 4:75062014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S, Xie C, Wang Q and Liu Z:
Interactions of CaMKII with dopamine D2 receptors: Roles in
levodopa-induced dyskinesia in 6-hydroxydopamine lesioned
Parkinson's rats. Sci Rep. 4:68112014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deininger MH, Meyermann R and Schluesener
HJ: The allograft inflammatory factor-1 family of proteins. FEBS
Lett. 514:115–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jalali-Nadoushan M and Roghani M:
Alpha-lipoic acid protects against 6-hydroxydopamine-induced
neurotoxicity in a rat model of hemi-parkinsonism. Brain Res.
1505:68–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perfeito R, Cunha-Oliveira T and Rego AC:
Reprint of: Revisiting oxidative stress and mitochondrial
dysfunction in the pathogenesis of Parkinson disease-resemblance to
the effect of amphetamine drugs of abuse. Free Radic Biol Med.
62:186–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schober A: Classic toxin-induced animal
models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res.
318:215–224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Norden DM, Trojanowski PJ, Villanueva E,
Navarro E and Godbout JP: Sequential activation of microglia and
astrocyte cytokine expression precedes increased Iba-1 or GFAP
immunoreactivity following systemic immune challenge. Glia.
64:300–316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
D'Amelio M, Sheng M and Cecconi F:
Caspase-3 in the central nervous system: Beyond apoptosis. Trends
Neurosci. 35:700–709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hald A and Lotharius J: Oxidative stress
and inflammation in Parkinson's disease: Is there a causal link?
Exp Neurol. 193:279–290. 2005. View Article : Google Scholar : PubMed/NCBI
|
